Pharma BD Deal Intelligence
Alnylam signs a $2.8 billion deal with Roche to advance the Cambridge biotech's injection for high blood pressure, with companies sharing development costs and…
Roche and Alnylam strike a $2.8 billion RNAi deal for zilebesiran, a subcutaneous hypertension treatment that suppresses angiotensinogen production with the…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Roche partnered with Alnylam to co-develop and co-commercialize zilebesiran, an RNAi therapeutic for hypertension in high cardiovascular risk patients, with Roche paying 60% of development costs. The program advanced into the global Phase 3 ZENITH cardiovascular outcomes trial (~11,000 patients, 35 countries); first-patient dosing on Oct 1, 2025 triggered a $300M milestone payment from Roche — the first major milestone realized under the agreement.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Alnylam Pharmaceuticals Inc. (this deal) | 2023 | $2.8B | 72 |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2023 deals · Roche Holding AG deals · Cardiovascular deals